1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,110 | 0,134 | 23.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.06. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 12.06. | SINOMAB BIO-B (03681): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 12 JUNE 2026 AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR | 5 | HKEx | ||
| 14.05. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT PRESENTATION OF PRECLINICAL STUDIES OF ANTI-CGC ANTIBODY (HC2) AT SID ANNUAL MEETING 2026 | 5 | HKEx | ||
| 13.05. | SinoMab BioScience Limited: Dr. Shui On Leung Invited to the 2026 LifeArc Translational Science Summit in the UK | 515 | JCN Newswire | HONG KONG, May 13, 2026 - (ACN Newswire) - SinoMab BioScience Limited ('SinoMab' or the 'Company', together with its subsidiaries, the 'Group' stock code: 03681.HK) is pleased to announce that Dr. Shui... ► Artikel lesen | |
| 27.04. | SINOMAB BIO-B (03681): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 2 | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | - | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): NOTICE OF 2026 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| SINOMAB BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 27.04. | SINOMAB BIO-B (03681): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD AT ROOM 3, 14/F, FAIRMONT HOUSE, 8 COTTON TREE DRIVE, CENTRAL, HONG KONG ... | 1 | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED ELECTION OF A DIRECTOR AND PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK ... | - | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): ANNUAL REPORT 2025 | 1 | HKEx | ||
| 01.04. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF SM17 FOR ATOPIC DERMATITIS IN CHINA | - | HKEx | ||
| 31.03. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 31.03. | SINOMAB BIO-B (03681): RESIGNATION OF NON-EXECUTIVE DIRECTORS | - | HKEx | ||
| 25.03. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT TOPLINE RESULTS FROM PHASE 1 BRIDGING STUDY FOR ROUTE OF ADMINISTRATION CONVERSION OF SM17 IN CHINA | - | HKEx | ||
| 24.03. | SINOMAB BIO-B (03681): GRANT OF SHARE OPTIONS | - | HKEx | ||
| 24.03. | SinoMab BioScience Limited: SinoMab (03681.HK) Achieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement | 411 | JCN Newswire | HONG KONG, Mar 24, 2026 - (ACN Newswire) - SinoMab BioScience Limited ('SinoMab' or the 'Company', together with its subsidiaries, the 'Group' stock code: 03681.HK) is pleased to announce its annual... ► Artikel lesen | |
| 23.03. | SINOMAB BIO-B (03681): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025; AND CHANGE IN USE OF PROCEEDS | 2 | HKEx | ||
| 12.03. | SINOMAB BIO-B (03681): CONNECTED TRANSACTION - TERMINATION OF LEASE AGREEMENT | - | HKEx | ||
| 10.03. | SINOMAB BIO-B (03681): DATE OF BOARD MEETING | - | HKEx |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,88 | +0,25 % | Apogee Therapeutics: Hier dürfte zum US-Handelsstart heute die Post abgehen! | AbbVie steht laut einem Bericht kurz vor der Übernahme von Apogee Therapeutics für rund 10,9 Milliarden US-Dollar in bar. Der mögliche Aufschlag liegt bei etwa 60 Prozent. Weil die US-Börsen am Freitag... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,310 | +1,31 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen | |
| BEAM THERAPEUTICS | 33,200 | -6,56 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| IMMUNOME | 19,330 | +0,78 % | Immunome Inc. - 8-K, Current Report | ||
| VERA THERAPEUTICS | 38,200 | -0,60 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| QIAGEN | 32,610 | +1,73 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen vor Zahlen zum zweiten Quartal auf "Buy" belassen. Diese dürften sich im Rahmen der eigenen Vorgaben des Diagnostikspezialisten... ► Artikel lesen | |
| TANGO THERAPEUTICS | 28,385 | -0,40 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| ADITXT | 0,042 | +117,19 % | Aditxt, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 305,35 | +0,65 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| RELAY THERAPEUTICS | 17,440 | +0,93 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,245 | -0,25 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| KYMERA THERAPEUTICS | 98,15 | -1,31 % | Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock? | ||
| TARSUS PHARMACEUTICALS | 66,22 | +4,18 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| DISC MEDICINE | 70,45 | -0,49 % | Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen | |
| BOUNDLESS BIO | 2,610 | +86,43 % | Boundless Bio, Inc.: Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement | Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha's lead program SERP-01 targets the... ► Artikel lesen |
SINOMAB BIOSCIENCE LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,001 (+0,88 %) liegt der Kurs bei 0,115 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SINOMAB BIOSCIENCE LTD finden Sie auf Wallstreet Online.